Bio-Rad Labs (NYSE: BIO) reported Q2 EPS of $0.97, $0.19 better than the analyst estimate of $0.78. Revenue for the quarter came in at $506.1 million versus the consensus estimate of $494.85 million.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.